

New Technologies Provide Options for Lung Cancer Detection

Lung cancer claims the lives of more people in the U.S. than breast, prostate, and colon cancers combined. Early detection can be the best method to determine the right course of action.

New technology is available to detect lung cancer earlier. Electromagnetic Navigational Bronchoscopy (ENB) is a minimally invasive bronchoscopic technique with GPS-like technology using natural airways to access small nodules. ENB is 10 times safer than commonly used CT-guided biopsies, and even more accurate. This technology collects enough samples to permit 'designer' chemotherapies and can deposit lung markers for more focused radiation therapy.

Endobronchial Ultrasound (EBUS) is also minimally invasive and allows doctors to detect if cancer has spread, sparing patients from major chest surgeries, and provides information regarding lung cancer stage.

Early detection is always the goal, and low-dose CT scans may lower cancer-attributable mortality by up to 20%. These low-dose CT scans are now covered by Medicare for those who qualify. Primary physicians will determine if a patient is eligible for the low-dose CT scan, and patients can be referred to the Kettering Health Network Lung Nodule Clinic to review their scan. "Our lung nodule clinic will help diagnose lung cancer in early stages and provide patients with a chance for a cure," says **Ehab Hussein, DO**.

Patients may be eligible for a CT lung screening if they:

- Are a current or former smoker
- Are age 55-74
- Are in good health – no signs or symptoms of lung disease
- Have no personal history of lung cancer
- Have a 30-pack-a-year smoking history
- Have quit within the last 15 years, if a former smoker

These advanced lung cancer services are provided at:

Fort Hamilton Hospital

- **Michael Gabrilovich, MD**

Grandview Medical Center

- **Patrick Allan, MD**

Kettering Medical Center

- **Ehab Hussein, DO**

- **Hemant Shah, MD**

**Coming in 2016: Kettering Health
Network Lung Nodule Clinic**

Network Only Site in Region to Offer Newly FDA-Approved Primary Glioblastoma Treatment

On October 6, 2015, the FDA approved Optune™ as a primary form treatment for glioblastoma.

Optune (formerly NovoTTF™-100A System) is an innovative, non-invasive treatment option for adult patients with newly diagnosed or recurrent glioblastoma. It is as effective as chemotherapy but has fewer side effects, offering a better quality of life.

Optune is a portable, helmet-like medical device that produces alternating electric fields or Tumor Treating Fields (TTFields), which can slow or stop cancer cells from dividing. It is designed to be worn continuously throughout the day and night and should be used for at least 18 hours a day to get the best response to treatment.

Kettering Physician Network Neuro-Oncologist **Herbert Newton, MD, FAAN**, is the only neuro-oncologist in the Greater Dayton area who is certified to prescribe and monitor Optune treatments.

To learn more about Optune and other neuro-oncology treatments, attend the 2016 Neuroscience Innovation Symposium on Wednesday, January 20, from 6-8 p.m. Call (937) 558-3457 for more information.

